New Report Benchmarks GSKs Performance Against Key Rivals in the Ethical Pharmaceutical Sector

Business Wire,  Nov 26, 2007  

• E-mail
• Print
• Link

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c75250) has announced the addition of Datamonitor's new report: GlaxoSmithKline: PharmaVitae Profile to their offering.

This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:

* Benchmark GSKs performance against key rivals in the ethical pharmaceutical sector

* Understand quantitatively how the relative balance of growth from launches and declines from expiries will leave GSKs revenues treadmilling 200511

* Evaluate the prospects of the companys Centres of Excellence in Drug Discovery R&D structure boosting long-term growth

Products Mentioned Include:

* Seretide/Advair

* Super Advair

* Allermist

* Flixonase/Flonase

* Avandia/Avandamet

* Wellbutrin

* Imigran/Imitrex

* Trexima

* Lamictal

* Cervarix

* Tykerb

* Zofran

* Avodart

Chapter 1.

Executive summary

Key findings

Historical and forecast ethical sales performance

Therapeutic strategy

Launch and expiry outlook

Externalization, geographic and molecule type strategies

Externalization strategy

Geographic strategy

Molecule type strategy

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

Chapter 2.

Corporate history

Key findings

Background

M&A history

Wellcome

Glaxo

Glaxo Wellcome

Beecham

Smith Kline

SmithKline Beecham

Key historical drug launches by component GSK companies

M&A strategy

R&D overview

Current corporate structure

Chapter 3.

Historical performance

Key findings

Introduction

Revenue and growth rate analysis, 2002-05

Revenue and growth rate vs. peer set

Product analysis, 2002-05

Key growth drivers

Growth resistors

Operating revenue and cost analysis, 2002-05

Operating revenue/cost analysis

Chapter 4.

Forecast performance

Key findings

Introduction

Revenue and growth rate, 2005-11

Product analysis, 2005-11

Growth drivers

Therapy area analysis, 2005-11

Urology

Oncology

Diabetes & endocrinology

CNS

Infectious disease

Respiratory

Therapy area focus

Launches and expiries analysis, 2005-11

Launch portfolio

Core portfolio

Expiry portfolio

Launch/core/expiry configuration

Externalization analysis, 2005-11

Geographic analysis, 2005-11

Molecule type analysis, 2005-11

Chapter 5.

Key products and competitors

Key findings

Overview

Seretide/Advair

Super Advair

Allermist

Flixonase/Flonase

Avandia/Avandamet

Wellbutrin

Imigran/Imitrex

Trexima

Lamictal

Cervarix

Tykerb

Zofran

Avodart

R&D pipeline

Chapter 6.

Appendix

IMS vs. company-reported data reconciliation

Abbreviations

Exchange rates

TABLE OF TABLES

TABLE OF FIGURES

For more information visit http://www.researchandmarkets.com/reports/c75250

Source: Datamonitor

COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning